BAX and PKCα modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia

Steven M. Kornblau, Ha T. Vu, Peter Ruvolo, Zeev Estrov, Susan O'Brien, Jorge Cortes, Hagop Kantarjian, Michael Andreeff, W. Stratford May

Research output: Contribution to journalArticle

Abstract

Previously, we demonstrated that the level of BCL2 expression is prognostic in acute myelogenous leukemia (AML). High levels of BCL2 correlate with an adverse outcome when associated with favorable and intermediate prognosis cytogenetics (FIPC), whereas low levels portend an adverse outcome when associated with unfavorable cytogenetics (UC). Because BCL2 function can be modulated by dimerization with family members, like BAX, or by phosphorylation by protein kinase C α (PKCα), we hypothesize that the relative expression of these proteins in primary leukemic cells might alter the prognostic impact of BCL2 expression. We therefore measured BAX and PKCα protein levels in peripheral blood mononuclear cell lysates from 165 newly diagnosed AML patients and correlated the expression of these proteins with BCL2 expression, patient survival, and remission induction success. Expression levels of BAX and PKCα were normalized against a control cell line, K562. BAX and PKCα expression levels were heterogeneous and did not correlate with the percentage of blasts in the sample (R2 = 0.01 and <0.01). The median expression of both was similar across FAB groups but the range was greater for M4. A similar distribution of expression was observed in all cytogenetic groups, except that patients with inversion 16 demonstrated lower levels of BAX. Individually, neither PKCα nor BAX expression was prognostic of response to induction therapy or survival. A similar outcome was obtained when patients were stratified by cytogenetics into FIPC and UC groups. However, the ratio of either BCL2:BAX (B2:BX) or PKCα*B2:BX (PK*B2:BX) was highly prognostic. Patients with FIPC and a lower ratio (less than median) of either B2:BX or PK*B2:BX had a significantly higher remission induction rate (88 versus 69%, P = 0.04) and longer survival (median: 141 versus 80.5 weeks, P = 0.007) compared with those with ratios more than median. For patients with UC, values of either B2:BX or PK*B2:BX below the median had an inferior response rate to induction therapy (35 versus 78%, P = 0.0006) and inferior survival outcomes (median survival: 11 versus 53 weeks, P = 0.00002). Interestingly, FIPC and UC patients with antiapoptotic ratios (defined as B2:BX or PK*B2:BX more than median) had identical response rates and survival outcomes. In multivariate analyses, the compound variables of cytogenetics and B2:BX, or PK*B2:BX were independent predictors of survival. These results suggest that expression levels of proteins that affect the functional status of BCL2 modify the prognostic impact of BCL2 and suggest that the role of apoptosis in different cases of AML varies independently in the different cytogenetic subgroups.

Original languageEnglish (US)
Pages (from-to)1401-1409
Number of pages9
JournalClinical Cancer Research
Volume6
Issue number4
StatePublished - Apr 1 2000
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Cytogenetics
Protein Kinase C
Survival
Remission Induction
Proto-Oncogene Proteins c-bcl-2
Proteins
Dimerization
Blood Cells
Multivariate Analysis
Survival Rate
Phosphorylation
Apoptosis
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kornblau, S. M., Vu, H. T., Ruvolo, P., Estrov, Z., O'Brien, S., Cortes, J., ... May, W. S. (2000). BAX and PKCα modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clinical Cancer Research, 6(4), 1401-1409.

BAX and PKCα modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. / Kornblau, Steven M.; Vu, Ha T.; Ruvolo, Peter; Estrov, Zeev; O'Brien, Susan; Cortes, Jorge; Kantarjian, Hagop; Andreeff, Michael; May, W. Stratford.

In: Clinical Cancer Research, Vol. 6, No. 4, 01.04.2000, p. 1401-1409.

Research output: Contribution to journalArticle

Kornblau, SM, Vu, HT, Ruvolo, P, Estrov, Z, O'Brien, S, Cortes, J, Kantarjian, H, Andreeff, M & May, WS 2000, 'BAX and PKCα modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia', Clinical Cancer Research, vol. 6, no. 4, pp. 1401-1409.
Kornblau SM, Vu HT, Ruvolo P, Estrov Z, O'Brien S, Cortes J et al. BAX and PKCα modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. Clinical Cancer Research. 2000 Apr 1;6(4):1401-1409.
Kornblau, Steven M. ; Vu, Ha T. ; Ruvolo, Peter ; Estrov, Zeev ; O'Brien, Susan ; Cortes, Jorge ; Kantarjian, Hagop ; Andreeff, Michael ; May, W. Stratford. / BAX and PKCα modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 4. pp. 1401-1409.
@article{4b239038f23a4117937db752600a92b4,
title = "BAX and PKCα modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia",
abstract = "Previously, we demonstrated that the level of BCL2 expression is prognostic in acute myelogenous leukemia (AML). High levels of BCL2 correlate with an adverse outcome when associated with favorable and intermediate prognosis cytogenetics (FIPC), whereas low levels portend an adverse outcome when associated with unfavorable cytogenetics (UC). Because BCL2 function can be modulated by dimerization with family members, like BAX, or by phosphorylation by protein kinase C α (PKCα), we hypothesize that the relative expression of these proteins in primary leukemic cells might alter the prognostic impact of BCL2 expression. We therefore measured BAX and PKCα protein levels in peripheral blood mononuclear cell lysates from 165 newly diagnosed AML patients and correlated the expression of these proteins with BCL2 expression, patient survival, and remission induction success. Expression levels of BAX and PKCα were normalized against a control cell line, K562. BAX and PKCα expression levels were heterogeneous and did not correlate with the percentage of blasts in the sample (R2 = 0.01 and <0.01). The median expression of both was similar across FAB groups but the range was greater for M4. A similar distribution of expression was observed in all cytogenetic groups, except that patients with inversion 16 demonstrated lower levels of BAX. Individually, neither PKCα nor BAX expression was prognostic of response to induction therapy or survival. A similar outcome was obtained when patients were stratified by cytogenetics into FIPC and UC groups. However, the ratio of either BCL2:BAX (B2:BX) or PKCα*B2:BX (PK*B2:BX) was highly prognostic. Patients with FIPC and a lower ratio (less than median) of either B2:BX or PK*B2:BX had a significantly higher remission induction rate (88 versus 69{\%}, P = 0.04) and longer survival (median: 141 versus 80.5 weeks, P = 0.007) compared with those with ratios more than median. For patients with UC, values of either B2:BX or PK*B2:BX below the median had an inferior response rate to induction therapy (35 versus 78{\%}, P = 0.0006) and inferior survival outcomes (median survival: 11 versus 53 weeks, P = 0.00002). Interestingly, FIPC and UC patients with antiapoptotic ratios (defined as B2:BX or PK*B2:BX more than median) had identical response rates and survival outcomes. In multivariate analyses, the compound variables of cytogenetics and B2:BX, or PK*B2:BX were independent predictors of survival. These results suggest that expression levels of proteins that affect the functional status of BCL2 modify the prognostic impact of BCL2 and suggest that the role of apoptosis in different cases of AML varies independently in the different cytogenetic subgroups.",
author = "Kornblau, {Steven M.} and Vu, {Ha T.} and Peter Ruvolo and Zeev Estrov and Susan O'Brien and Jorge Cortes and Hagop Kantarjian and Michael Andreeff and May, {W. Stratford}",
year = "2000",
month = "4",
day = "1",
language = "English (US)",
volume = "6",
pages = "1401--1409",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - BAX and PKCα modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia

AU - Kornblau, Steven M.

AU - Vu, Ha T.

AU - Ruvolo, Peter

AU - Estrov, Zeev

AU - O'Brien, Susan

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Andreeff, Michael

AU - May, W. Stratford

PY - 2000/4/1

Y1 - 2000/4/1

N2 - Previously, we demonstrated that the level of BCL2 expression is prognostic in acute myelogenous leukemia (AML). High levels of BCL2 correlate with an adverse outcome when associated with favorable and intermediate prognosis cytogenetics (FIPC), whereas low levels portend an adverse outcome when associated with unfavorable cytogenetics (UC). Because BCL2 function can be modulated by dimerization with family members, like BAX, or by phosphorylation by protein kinase C α (PKCα), we hypothesize that the relative expression of these proteins in primary leukemic cells might alter the prognostic impact of BCL2 expression. We therefore measured BAX and PKCα protein levels in peripheral blood mononuclear cell lysates from 165 newly diagnosed AML patients and correlated the expression of these proteins with BCL2 expression, patient survival, and remission induction success. Expression levels of BAX and PKCα were normalized against a control cell line, K562. BAX and PKCα expression levels were heterogeneous and did not correlate with the percentage of blasts in the sample (R2 = 0.01 and <0.01). The median expression of both was similar across FAB groups but the range was greater for M4. A similar distribution of expression was observed in all cytogenetic groups, except that patients with inversion 16 demonstrated lower levels of BAX. Individually, neither PKCα nor BAX expression was prognostic of response to induction therapy or survival. A similar outcome was obtained when patients were stratified by cytogenetics into FIPC and UC groups. However, the ratio of either BCL2:BAX (B2:BX) or PKCα*B2:BX (PK*B2:BX) was highly prognostic. Patients with FIPC and a lower ratio (less than median) of either B2:BX or PK*B2:BX had a significantly higher remission induction rate (88 versus 69%, P = 0.04) and longer survival (median: 141 versus 80.5 weeks, P = 0.007) compared with those with ratios more than median. For patients with UC, values of either B2:BX or PK*B2:BX below the median had an inferior response rate to induction therapy (35 versus 78%, P = 0.0006) and inferior survival outcomes (median survival: 11 versus 53 weeks, P = 0.00002). Interestingly, FIPC and UC patients with antiapoptotic ratios (defined as B2:BX or PK*B2:BX more than median) had identical response rates and survival outcomes. In multivariate analyses, the compound variables of cytogenetics and B2:BX, or PK*B2:BX were independent predictors of survival. These results suggest that expression levels of proteins that affect the functional status of BCL2 modify the prognostic impact of BCL2 and suggest that the role of apoptosis in different cases of AML varies independently in the different cytogenetic subgroups.

AB - Previously, we demonstrated that the level of BCL2 expression is prognostic in acute myelogenous leukemia (AML). High levels of BCL2 correlate with an adverse outcome when associated with favorable and intermediate prognosis cytogenetics (FIPC), whereas low levels portend an adverse outcome when associated with unfavorable cytogenetics (UC). Because BCL2 function can be modulated by dimerization with family members, like BAX, or by phosphorylation by protein kinase C α (PKCα), we hypothesize that the relative expression of these proteins in primary leukemic cells might alter the prognostic impact of BCL2 expression. We therefore measured BAX and PKCα protein levels in peripheral blood mononuclear cell lysates from 165 newly diagnosed AML patients and correlated the expression of these proteins with BCL2 expression, patient survival, and remission induction success. Expression levels of BAX and PKCα were normalized against a control cell line, K562. BAX and PKCα expression levels were heterogeneous and did not correlate with the percentage of blasts in the sample (R2 = 0.01 and <0.01). The median expression of both was similar across FAB groups but the range was greater for M4. A similar distribution of expression was observed in all cytogenetic groups, except that patients with inversion 16 demonstrated lower levels of BAX. Individually, neither PKCα nor BAX expression was prognostic of response to induction therapy or survival. A similar outcome was obtained when patients were stratified by cytogenetics into FIPC and UC groups. However, the ratio of either BCL2:BAX (B2:BX) or PKCα*B2:BX (PK*B2:BX) was highly prognostic. Patients with FIPC and a lower ratio (less than median) of either B2:BX or PK*B2:BX had a significantly higher remission induction rate (88 versus 69%, P = 0.04) and longer survival (median: 141 versus 80.5 weeks, P = 0.007) compared with those with ratios more than median. For patients with UC, values of either B2:BX or PK*B2:BX below the median had an inferior response rate to induction therapy (35 versus 78%, P = 0.0006) and inferior survival outcomes (median survival: 11 versus 53 weeks, P = 0.00002). Interestingly, FIPC and UC patients with antiapoptotic ratios (defined as B2:BX or PK*B2:BX more than median) had identical response rates and survival outcomes. In multivariate analyses, the compound variables of cytogenetics and B2:BX, or PK*B2:BX were independent predictors of survival. These results suggest that expression levels of proteins that affect the functional status of BCL2 modify the prognostic impact of BCL2 and suggest that the role of apoptosis in different cases of AML varies independently in the different cytogenetic subgroups.

UR - http://www.scopus.com/inward/record.url?scp=0033624762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033624762&partnerID=8YFLogxK

M3 - Article

C2 - 10778970

AN - SCOPUS:0033624762

VL - 6

SP - 1401

EP - 1409

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -